| Index | — | P/E | — | EPS (ttm) | -4.49 | Insider Own | 5.54% | Shs Outstand | 112.48M | Perf Week | -10.42% |
| Market Cap | 483.67M | Forward P/E | 12.08 | EPS next Y | 0.36 | Insider Trans | -1.06% | Shs Float | 102.41M | Perf Month | 26.84% |
| Enterprise Value | 1.34B | PEG | — | EPS next Q | 0.06 | Short Float | 11.62% | Perf Quarter | 36.94% | ||
| Income | -505.00M | P/S | 0.23 | EPS this Y | 165.03% | Short Ratio | 3.91 | Perf Half Y | 14.67% | ||
| Sales | 2.10B | P/B | 1.26 | EPS next Y | 108.98% | ROA | -25.61% | Short Interest | 11.90M | Perf YTD | 7.50% |
| Book/sh | 3.40 | P/C | 4.17 | EPS next 5Y | 49.47% | ROE | -99.16% | 52W High | 7.10 -39.44% | Perf Year | -39.27% |
| Cash/sh | 1.03 | P/FCF | 28.45 | EPS past 3/5Y | — | ROIC | -1.94% | 52W Low | 2.10 104.76% | Perf 3Y | -83.14% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 11.54% 15.19% | Gross Margin | 12.91% | Volatility | 6.06% 6.52% | Perf 5Y | -85.77% |
| Dividend TTM | — | EV/Sales | 0.64 | EPS Y/Y TTM | — | Oper. Margin | -1.37% | ATR (14) | 0.26 | Perf 10Y | -81.92% |
| Dividend Ex-Date | — | Quick Ratio | 1.24 | Sales Y/Y TTM | -4.46% | Profit Margin | -24.08% | RSI (14) | 49.16 | Recom | 2.23 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.24 | EPS Q/Q | 120.00% | SMA20 | -2.62% | Beta | 0.98 | Target Price | 7.00 |
| Payout | — | Debt/Eq | 2.53 | Sales Q/Q | 47.07% | SMA50 | 2.49% | Rel Volume | 0.46 | Prev Close | 4.25 |
| Employees | 4,200 | LT Debt/Eq | 2.53 | Earnings | Nov 05 | SMA200 | 11.13% | Avg Volume | 2.47M | Price | 4.30 |
| IPO Date | Jun 05, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 292.10% 9.17% | Net Debt/EBITDA | — | Volume | 1,145,975 | Change | 1.18% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-11-26 | Upgrade | Citigroup | Neutral → Buy | |
| Jul-23-26 | Downgrade | Citigroup | Buy → Neutral | |
| Jul-21-26 | Reiterated | Canaccord Genuity | Buy | $6.00 → $7.00 |
| Jun-30-26 | Downgrade | Truist Securities | Buy → Hold | $6.00 → $7.00 |
| May-12-26 | Reiterated | Canaccord Genuity | Buy | $6.00 |
| Feb-25-26 | Reiterated | BMO Capital | $3.50 | |
| Feb-25-26 | Downgrade | Keybanc | Overweight → Sector Weight | |
| Feb-02-26 | Reiterated | BTIG | Buy | $10 |
| Dec-02-25 | Reiterated | Piper Sandler | Overweight | $6.00 |
| Jan-16-25 | Reiterated | UBS | Buy | $14 |
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,098 | 1,876 | 2,555 | 1,964 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,827 | 1,592 | 2,187 | 1,503 | — | — | — | — | — | |
| Gross Profit | 271 | 284 | 367 | 460 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 278 | 288 | 263 | 358 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 21 | 0 | 145 | 174 | — | — | — | — | — | |
| Operating Income | -29 | -4 | -40 | -71 | — | — | — | — | — | |
| Interest Expense | 69 | 57 | 25 | 54 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -404 | -473 | 2 | -77 | — | — | — | — | — | |
| Net Income Before Taxes | -503 | -535 | -63 | -202 | — | — | — | — | — | |
| Income Taxes | 3 | 0 | -1 | -89 | — | — | — | — | — | |
| Consolidated Net Income | -505 | -535 | -62 | -113 | — | — | — | — | — | |
| Net Income From Continuing Operations | -505 | -535 | -62 | -113 | — | — | — | — | — | |
| Net Income | -505 | -535 | -62 | -113 | — | — | — | — | — | |
| EPS (Recurring) | -4.49 | -5.07 | -0.81 | -1.28 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.49 | -5.07 | -0.81 | -1.28 | — | — | — | — | — | |
| EPS (Diluted) | -4.49 | -5.07 | -0.81 | -1.28 | — | — | — | — | — | |
| EBITDA | -320 | -361 | 80 | -25 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.23 | 0.24 | 0.51 | 1.87 | — | — | — | — | — | |
| Gross Margin | 12.92 | 15.14 | 14.36 | 23.42 | — | — | — | — | — | |
| Operating Margin | -1.38 | -0.21 | -1.57 | -3.62 | — | — | — | — | — | |
| Net Margin | -24.07 | -28.52 | -2.43 | -5.75 | — | — | — | — | — | |
| Shares Outstanding | 113 | 114 | 115 | 111 | — | — | — | — | — | |
| Market Capitalization | 486 | 456 | 1,294 | 3,666 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McCarthy Daniel Joseph | PRESIDENT | Aug 26 '26 | Sale | 5.00 | 65,892 | 329,460 | 655,133 | Aug 28 |
| Springstubb Brendan B | Director | Nov 18 '25 | Buy | 3.82 | 10,000 | 38,199 | 58,821 | Nov 19 |
| Springstubb Brendan B | Director | Mar 07 '25 | Buy | 9.27 | 15,000 | 139,050 | 26,842 | Mar 10 |
| Jelinek Richard M | Director | Mar 07 '25 | Buy | 9.13 | 30,000 | 273,750 | 15,000 | Mar 10 |
| KECK KIM | Director | Mar 07 '25 | Buy | 9.44 | 10,540 | 99,498 | 39,522 | Mar 10 |
| McCarthy Daniel Joseph | PRESIDENT | Mar 06 '25 | Buy | 9.01 | 11,040 | 99,470 | 389,004 | Mar 10 |
| Holder Diane | Director | Mar 06 '25 | Buy | 9.33 | 2,735 | 25,518 | 70,584 | Mar 10 |
| GRUA PETER J | Director | Mar 06 '25 | Buy | 9.01 | 11,040 | 99,470 | 18,749 | Mar 10 |
| Blackley Seth | Chief Executive Officer | Mar 06 '25 | Buy | 9.01 | 55,225 | 497,577 | 762,217 | Mar 10 |
| Glass Russell Monroe | Director | Mar 06 '25 | Buy | 9.27 | 5,400 | 50,058 | 14,272 | Mar 10 |
| Barbarosh Craig A. | Director | Mar 06 '25 | Buy | 8.81 | 2,000 | 17,620 | 31,956 | Mar 10 |
| Springstubb Brendan B | Director | Mar 04 '25 | Buy | 8.75 | 5,000 | 43,750 | 11,842 | Mar 05 |
| McCarthy Daniel Joseph | PRESIDENT | Aug 23 '24 | Sale | 32.38 | 10,469 | 339,008 | 188,340 | Aug 26 |
| McCarthy Daniel Joseph | PRESIDENT | Aug 22 '24 | Sale | 30.89 | 23,693 | 731,790 | 198,809 | Aug 26 |
| McCarthy Daniel Joseph | PRESIDENT | Aug 22 '24 | Option Exercise | 24.75 | 4,550 | 112,613 | 222,502 | Aug 26 |